Korro Bio, Inc. (NASDAQ: KRRO) is a Healthcare company (Biotechnology) with a market capitalization of $183M. The Maz Rating grades it against the other companies in its sector.
Korro Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.71, Korro Bio, Inc. trades at 144.1x sales and 2.6x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $129M. It runs a gross margin of 49.8%, an operating margin of -5796.1% and a net margin of -8214.5%. It shows return on equity of -117.1%, return on invested capital of -55.0% and a free cash flow yield of -34.8%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 7.30. Over the past 52 weeks the share price ranged from $5.20 to $17.35, with a beta of 2.36.
Korro Bio, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Korro Bio, Inc. (KRRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 58.3% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 49.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 49.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 67.2% / 33.33% · Receivables / Avg Assets (4Q) 0.16% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 70.9% / 33.33% · (Cash+Recv) / Total Assets 70.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Korro Bio, Inc. (KRRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Korro Bio, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Korro Bio, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.